Why this matters in 2026
Ibogaine remains a Schedule I substance in the United States, so conventional clinical access is limited. Interest has surged among people with opioid and stimulant use disorders and trauma backgrounds, while U.S. activity is largely confined to early trials and narrow Right‑to‑Try pathways. Mexico has become the primary access hub due to proximity, a legal gray area, and significantly lower costs versus Costa Rica, Europe, or Canada. Programs are not covered by U.S. insurance and are paid fully out‑of‑pocket, making cost‑quality trade‑offs critical.
For broader legal and context reading, see an overview of ibogaine treatment in the United States. The U.S. Drug Enforcement Administration identifies ibogaine in its drug scheduling information, a relevant starting point when comparing cross-border access with domestic clinical pathways.